TYLENOL WITH NAPROXEN Drug Patent Profile
Which patents cover Tylenol With Naproxen, and when can generic versions of Tylenol With Naproxen launch?
Tylenol With Naproxen is a drug marketed by Kenvue Brands and is included in one NDA.
The generic ingredient in TYLENOL WITH NAPROXEN is acetaminophen; naproxen sodium. There is one drug master file entry for this compound. Additional details are available on the acetaminophen; naproxen sodium profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for TYLENOL WITH NAPROXEN?
- What are the global sales for TYLENOL WITH NAPROXEN?
- What is Average Wholesale Price for TYLENOL WITH NAPROXEN?
Summary for TYLENOL WITH NAPROXEN
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Clinical Trials: | 9 |
| DailyMed Link: | TYLENOL WITH NAPROXEN at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for TYLENOL WITH NAPROXEN
Generic Entry Date for TYLENOL WITH NAPROXEN*:
Constraining patent/regulatory exclusivity:
NEW PRODUCT NDA:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for TYLENOL WITH NAPROXEN
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| University of Oklahoma | PHASE4 |
| University of Toronto | Phase 4 |
| Humber River Hospital | Phase 4 |
US Patents and Regulatory Information for TYLENOL WITH NAPROXEN
TYLENOL WITH NAPROXEN is protected by zero US patents and one FDA Regulatory Exclusivity.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of TYLENOL WITH NAPROXEN is ⤷ Start Trial.
This potential generic entry date is based on NEW PRODUCT.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kenvue Brands | TYLENOL WITH NAPROXEN | acetaminophen; naproxen sodium | TABLET;ORAL | 219962-001 | Jul 24, 2026 | OTC | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
